



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: O'Brien et al.

FILED: October 20, 1999

SERIAL NO.: 09/421,213

FOR: TADG-15: An Extracellular Serine  
Protease Overexpressed In Carcinomas

§ ART UNIT:  
§ 1642  
§  
§ EXAMINER:  
§ Harris, A.  
§  
§ DOCKET:  
§ D6064CIP

The Honorable Commissioner of Patents  
BOX NON-FEE AMENDMENT  
Washington, DC 20231

RESPONSE UNDER 37 C.F.R. § 1.111

Dear Sir:

In response to the Office Action mailed April 3, 2002, please enter the following amendments and remarks. Reconsideration of the pending claims is respectfully requested.

AMENDMENTS

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 9, line 19, with the following rewritten paragraph:

Figures 1A and 1B show a comparison of the serine protease catalytic domain of TADG-15 with Hepsin (Heps, SEQ ID No. 3), SCCE (SEQ ID No. 4), Trypsin, (Try, SEQ ID No. 5), Chymotrypsin (Chymb,

#  
24/F  
KD  
9-13m

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

F1